Form 4/A for ALDX Aldeyra Therapeutics, Inc.
Accepted 2024-04-17 00:00:00 ET · period of report 2024-03-11 · accession 0000950170-24-045108 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-04-17 | 2024-03-11 | ALDX | Greenberg Bruce | See Remarks | S - Sale | $3.41 | -13.2K | 130.2K | -9% | -$45.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-11 | S | D | 13,201 | $3.41 | 130,154 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Adjusted to reflect 9,455 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment. |